Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Shiseido: Domestic Sales Down for Both Cosmetics, Toiletries
May 27, 2002
- Pharmacies Employ Largest Number of Pharma Graduates
May 27, 2002
- Household Healthcare Costs Up 3.2%
May 27, 2002
- BMS: 1st Qtr Sales Down 7.0% to US$4.3 Bil.
May 27, 2002
- 12-hour Night Shift Work for Nurses Increasing: JNA Survey
May 27, 2002
- Eiken: Sales Up 2.5% to \21.3 Bil., Net Profits Up 44.4% to \1.2 Bil.
May 27, 2002
- JHSF Urges Makers to Beef Up Int'l Competitiveness in Genomic Drug Discovery
May 20, 2002
- WORLD NEWS IN BRIEF
May 20, 2002
- Trends in Informatics Reported by JHSF
May 20, 2002
- R&D Synergy to Accelerate Antibody Therapeutics: Chugai, Roche
May 20, 2002
- Increases in CAM-Resistant Hp Require Alternative Regimens
May 20, 2002
- Kumakura to Follow Path of His Predecessor: Kuraya Sanseido
May 20, 2002
- Epidural PCA Effective for Postoperative Pain
May 20, 2002
- JPMA Committee to Promote Patient-friendly Healthcare
May 20, 2002
- Kobe Foundation, Kirin to Commercialize Cord Blood Stem Cells
May 20, 2002
- Importance of Drug Patents Emphasized: Union Symposium
May 20, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
May 20, 2002
- Teijin to Form Teijin Pharma by Spinning Off Drug Division in 2003
May 20, 2002
- Terumo to Transfer Dialyzer Business to Asahi Medical
May 20, 2002
- BUSINESS NEWS IN BRIEF
May 20, 2002
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…